Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group's self-developed drug TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.20 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD for the second quarter, returning to profitability year-on-year [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinke (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - China Star Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company for the first half of the year [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Major Events - Cathay Pacific (00293) has purchased fourteen Boeing 777-9 aircraft [1] - Hengrui Medicine (01276) received FDA orphan drug designation for the combination of injection Rituximab and chemotherapy for gastric cancer or gastroesophageal junction adenocarcinoma [1] - China National Pharmaceutical Group (01177) has its self-developed drug TQ05105 (JAK/ROCK inhibitor) included in the breakthrough therapy designation program [1] - Junshi Biosciences (02696) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanli Kang® for active glomerulonephritis in China [1] - YingTai Medical (01501) plans to invest no more than 110 million yuan to establish the Huai Ge Guang Tai Fund [1] - JinJing New Energy (01783) proposed a stock split [1] Financial Data - Cathay Pacific (00293) reported a mid-term profit attributable to shareholders of 3.651 billion HKD, a year-on-year increase of 1.1%, with an interim dividend of 0.2 HKD per share [1] - Uni-President Enterprises China (00220) reported a mid-term profit attributable to shareholders of 1.287 billion CNY, a year-on-year increase of 33.24% [1] - BeiGene (06160) reported a net profit of 94.32 million USD in the second quarter, returning to profitability year-on-year [1] - New World Development Company (00086) issued a profit warning, expecting mid-term profit attributable to shareholders to increase to no less than 800 million HKD year-on-year [1] - Weixin Jinkao (02003) issued a profit warning, expecting mid-term comprehensive net profit to be no less than 200 million CNY, a significant year-on-year increase [1] - ZhiZi Cheng Technology (09911) issued a profit warning, expecting mid-term profit attributable to shareholders to increase by approximately 108.9% to 126.7% year-on-year [1] - Huaxian Optoelectronics (00334) issued a profit warning, expecting a year-on-year increase of no less than 600% in profit attributable to the parent company [1] - Xinli International (00732) reported a total operating revenue of approximately 1.468 billion HKD in July, a year-on-year decrease of about 3.3% [1]

Performance Highlights - BeiGene (06160.HK) reported a revenue of 17.518 billion yuan for the first half of the year, a year-on-year increase of 46%; product revenue was 17.36 billion yuan, up 45.8%; net profit was 450 million yuan, turning from loss to profit [2] - Uni-President China (00220.HK) achieved approximately 17.087 billion yuan in revenue for the first half, a year-on-year increase of 10.6%; net profit was about 1.287 billion yuan, up 33.2% [2] - Zhiyu City Technology (09911.HK) announced a positive profit forecast, expecting mid-term revenue of approximately 3.135 to 3.215 billion yuan, a year-on-year increase of about 38.0% to 41.5%; net profit is expected to be around 470 to 510 million yuan, a year-on-year growth of approximately 108.9% to 126.7% [2] Earnings Forecasts - New World Development Company (00086.HK) expects mid-term net profit to increase to no less than 800 million HKD year-on-year [3] - Weizhi Jinkou (02003.HK) anticipates mid-term net profit exceeding 200 million HKD, a significant increase year-on-year [3] - Wing Chan Industrial (01596.HK) forecasts mid-term net profit of approximately 48.7 million HKD, turning from loss to profit [3] - Huaxian Optoelectronics (00334.HK) expects mid-term net profit to exceed 48.8 million HKD, a year-on-year increase of over 600% [3] - Maifushi (02556.HK) predicts mid-term net profit of approximately 31.8 to 41 million HKD, turning from loss to profit [4] - Xinwei Medical-B (06609.HK) expects mid-term net profit to exceed 40 million HKD, turning from loss to profit [5] - China Nuclear Technology (00611.HK) anticipates mid-term net profit growth of over 15% [6] Earnings Warnings - Hongxing Printing Group (00450.HK) expects mid-term net loss of approximately 49 million HKD, a significant increase year-on-year [7] - Zhongyu Land (01224.HK) forecasts mid-term net loss of approximately 40 million HKD, turning from profit to loss [7] - Beihai Group (00701.HK) anticipates mid-term net loss of 36 to 40 million HKD [8] Real Estate Sales Data - China Overseas Development (00688.HK) reported cumulative contract property sales of approximately 132 billion yuan for the first seven months, a year-on-year decrease of 18.3% [9] - Yuexiu Property (00123.HK) achieved cumulative contract sales of approximately 67.506 billion yuan for the first seven months, a year-on-year increase of about 11.7% [9] - Poly Property Group (00119.HK) reported contract sales of approximately 29.5 billion yuan for the first seven months, a year-on-year decrease of 13.49% [10] - China Overseas Hongyang Group (00081.HK) reported cumulative contract sales of 18.649 billion yuan for the first seven months, a year-on-year decrease of 12.2% [10] - Jindi Commercial Real Estate (00535.HK) reported cumulative contract sales of approximately 6.98 billion yuan for the first seven months, a year-on-year decrease of 37.37% [10] - Agile Group (03383.HK) reported pre-sale amount of approximately 5.69 billion yuan for the first seven months [11] - Hongyang Real Estate (01996.HK) reported cumulative contract sales of 3.208 billion yuan for the first seven months, a year-on-year decrease of 41.6% [12] - Zhengrong Real Estate (06158.HK) reported cumulative contract sales of approximately 2.701 billion yuan for the first seven months, a year-on-year decrease of 30.6% [12] - Jingrui Holdings (01862.HK) reported cumulative contract sales of approximately 571 million yuan for the first seven months, a year-on-year decrease of 52.54% [13] Company News - CITIC Securities (06030.HK) reported that its subsidiary, Huaxia Fund, achieved revenue of 4.258 billion yuan and net profit of 1.123 billion yuan in the first half, with assets under management totaling 285.1237 billion yuan [14] - Xinyi International (00732.HK) reported a cumulative operating revenue of approximately 9.566 billion HKD for the first seven months, a year-on-year decrease of about 5.3% [15] - Heng Rui Pharmaceutical (01276.HK) received orphan drug designation from the US FDA for its injection of Rikan Trastuzumab combined with Adebali for gastric cancer or gastroesophageal junction adenocarcinoma indications [15] - Fuhong Hanlin (02696.HK) completed the first patient dosing in a Phase II clinical study of HLX79 injection combined with Hanlikang® for active renal glomerulonephritis in China [15] - China Biopharmaceutical (01177.HK) announced that its self-developed TQ05105 (JAK/ROCK inhibitor) has been included in the breakthrough therapy designation program for the treatment of chronic graft-versus-host disease [15] Buyback Activities - HSBC Holdings (00005.HK) repurchased approximately 1.65 billion HKD worth of about 1.714 million shares at a price of 95.8 to 96.75 HKD [16] - Hang Seng Bank (00011.HK) spent approximately 22.6347 million HKD to repurchase 200,000 shares at a price of 112.8 to 113.6 HKD [17] - Yum China (09987.HK) repurchased approximately 6.264 million HKD worth of 16,800 shares at a price of 369.8 to 376 HKD [17]

格隆汇8月6日丨恒瑞医药(01276.HK)发布公告，近日，公司产品注射用瑞康曲妥珠单抗联合阿得贝利单 抗注射液和化疗用于胃癌或胃食管结合部腺癌适应症获得美国食品药品监督管理局(以下简称"美国 FDA")授予的孤儿药资格认定。孤儿药又称罕见病药，是指用于预防、治疗、诊断罕见病的药品。本次 公司获得美国FDA孤儿药资格认定，将有机会在产品研发、注册及商业化等方面享受美国的政策支持。 本次注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗用于胃癌或胃食管结合部腺癌适应症获得孤 儿药资格认定后，能够加快推进临床试验及上市注册的进度。同时，可享受一定的政策支持，包括但不 限于临床试验费用的税收抵免、免除新药申请费、产品获批后将享受 7 年的市场独占权。 ...

本次注射用瑞康曲妥珠单抗联合阿得贝利单抗注射液和化疗用于胃癌或胃食管结合部腺癌适应症获得孤 儿药资格认定后，能够加快推进临床试验及上市注册的进度。同时，可享受一定的政策支持，包括但不 限于临床试验费用的税收抵免、免除新药申请费、产品获批后将享受 7 年的市场独占权。 智通财经APP讯，恒瑞医药(01276)公布，近日，公司产品注射用瑞康曲妥珠单抗联合阿得贝利单抗注射 液和化疗用于胃癌或胃食管结合部腺癌适应症获得美国食品药品监督管理局(以下简称"美国 FDA")授予 的孤儿药资格认定。孤儿药又称罕见病药，是指用于预防、治疗、诊断罕见病的药品。本次公司获得美 国 FDA 孤儿药资格认定，将有机会在产品研发、注册及商业化等方面享受美国的政策支持。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因依賴 該等內容而引致的任何損失承擔任何責任。 Jiangsu Hengrui Pharmaceuticals Co., Ltd. （股份代號：1276） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條刊發。 根據中華人民共和國的有關法例規定，江蘇恒瑞醫藥股份有限公司（「本公司」）在 上海證券交易所網站( www.sse.com.cn )刊發了以下公告。茲載列如下，僅供參閱。 承董事會命 江蘇恒瑞醫藥股份有限公司 董事長 孫飄揚先生 中國上海 2025年8月6日 於本公告日期，董事會成員包括(i)執行董事孫飄揚先生、戴洪斌先生、馮佶女 士、張連山先生、江寧軍先生及孫杰平先生；(ii)非執行董事郭叢照女士；及(iii) 獨立非執行董事董家鴻先生、曾慶生先生、孫金雲先生及周紀恩先生。 证券代码：600276 证券简称：恒瑞医药 公告编号：临 2025-112 江蘇恒瑞醫藥股份有限公司 （於中華人民共和國註冊成立的股份有限公司） ...

智通财经APP获悉，截止8月6日收盘，东北电气(00042)、弘业期货(03678)、安德利果汁(02218)分列AH 溢价率前三位，溢价率分别为847.37%、230.56%、207.56%；宁德时代(03750)、恒瑞医药(01276)、药 明康德(02359)分列AH溢价率末三位，溢价率分别为-22.99%、-7.83%、7.16%。其中安德利果汁 (02218)、金力永磁(06680)、农业银行(01288)的偏离值位居前三，分别为26.19%、18.37%、14.05%；另 外，比亚迪股份(01211)、晨鸣纸业(01812)、东北电气(00042)的偏离值位居后三，分别 为-192.75%、-57.57%、-50.52%。 前十大AH股溢价率排行 | 钧达股份(02865) | | | | | | --- | --- | --- | --- | --- | | 山东墨龙(00568) | 4.540 | 6.59 | 73.79% | 7.87% | | 邮储银行(01658) | 5.560 | 5.9 | 27.16% | 7.75% | | 东江环保(00895) | 2.660 | 4.7 ...

大摩称，本季以来，主动基金增持最多的板块是传媒与娱乐、制药和保险，减持最多的是消费服务、耐 用消费品与服装。从个股看，腾讯(00700)、网易(09999)、恒瑞医药(01276)和药明康德(02359)获增持最 多，美团(03690)和小米(01810)减持最多。 大摩报告表示，7月外资净流入达27亿美元，高于6月的12亿美元。截至7月31日，今年以来境外被动型 资金累计流入达110亿美元，超过2024年全年70亿美元的水平，境外主动型资金累计流出达110亿美元， 也低于2024年全年。 智通财经APP获悉，大摩表示，外资基金7月加速净流入中国股市，其中被动型基金流入39亿美元，主 动型基金则流出12亿美元。被动型基金主要集中在月底入场，恰逢多项"反内卷"政策发布。 大摩表示，7月南向资金流入港股进一步提速至170亿美元，高于6月的100亿美元。今年前7个月累计净 流入达1100亿美元，超过2024年全年的1030亿美元。 ...

Summary of the Conference Call for 恒瑞医药 Company Overview - **Company**: 恒瑞医药 (Hengrui Medicine) - **Industry**: Pharmaceutical Key Points and Arguments Financial Projections - Expected domestic sales revenue growth of over 15% in 2025, with innovative drugs growing over 25% and generic drugs stabilizing [2][5] - Anticipated overseas licensing revenue exceeding $500 million, with total revenue growth projected at over 19% [2][5] - Net profit expected to reach 8.7 billion RMB, a year-on-year increase of 38% [2][5] Innovation and Product Pipeline - Focus on innovative drugs as a key growth driver, with several major products and indications launched, such as 白介 17, Jack one, and HER2 ADC [2][6] - Projected sales for innovative drugs to reach 17.4 billion RMB in 2025, contributing over 3.4 billion RMB to net profit [2][6] - R&D pipeline includes over 30 projects ranked in the top three globally, enhancing market competitiveness and valuation flexibility [2][7] International Expansion - Multiple overseas projects in progress, including a $200 million LPA project and 11 preclinical projects worth $500 million [2][9] - Expected BD (business development) revenue to exceed $575 million in 2025, contributing over 3 billion RMB to profits [2][9] Investment Logic - Investment logic based on three pillars: 1. Product harvest period leading to accelerated internal growth and valuation recovery [3] 2. Overseas market as a second growth curve with sustainable revenue potential [3] 3. Early-stage R&D pipeline targeting best-in-class or first-in-class products [3] Competitive Landscape - Transition from a fast-follow strategy to a best-in-class and first-in-class approach, with a competitive edge in ADC (antibody-drug conjugate) products [3][12] - Significant advancements in ADC products, with global clinical progress ranking among the fastest [21][20] Market Dynamics - Domestic market expected to achieve significant growth over the next three years, driven by the approval of heavyweight products [14] - The company’s innovative drug sales are projected to maintain a rapid growth trend, supported by favorable policy changes [6][14] R&D Efficiency - R&D expense ratio reached a historical high in 2024, with expectations for improvement in efficiency and a stable ratio around 20% in the future [8][31] - Enhanced R&D efficiency is anticipated to drive net profit growth faster than revenue growth [8] Valuation Model - Valuation model includes six components: 1. PE valuation for generic drugs 2. PS valuation based on peak sales for innovative drugs 3. PS valuation for early-stage pipeline 4. PS valuation for overseas projects 5. Potential overseas market space 6. Best-in-class and first-in-class product potential [30] Future Growth Drivers - Key factors influencing future market performance include product performance, successful international expansion, and the realization of early-stage pipeline value [31] Additional Important Insights - The company has established a strong presence in four major therapeutic areas: oncology, metabolic and cardiovascular diseases, immune and respiratory diseases, and neuroscience [18] - Continuous exploration of various internationalization models, including partnerships and direct licensing [15][17] - The company’s innovative strategies in treating diseases like psoriasis and KRAS-targeted therapies demonstrate a deep understanding of disease mechanisms [29][22] This summary encapsulates the essential insights from the conference call, highlighting the company's growth strategies, financial outlook, and competitive positioning within the pharmaceutical industry.

| 股票名称 | H股(港元) | A股 | 溢价率 | 偏离值↓ | | --- | --- | --- | --- | --- | | 安德利果汁(02218) | 18.490 | 47.1 | 205.14% | 24.54% | | 金力永磁(06680) | 18.700 | 27.1 | 73.58% | 15.57% | | 北京北辰实业股份 (00588) | 0.860 | 1.77 | 146.51% | 12.95% | | 农业银行(01288) | 5.380 | 6.54 | 45.54% | 10.57% | | 弘业期货(03678) | 4.350 | 12.3 | 238.62% | 10.03% | | 东江环保(00895) | 2.660 | 4.76 | 114.29% | 9.15% | | 浙江世宝(01057) | 5.250 | 12.56 | 186.48% | 8.63% | | 钧达股份(02865) | 21.700 | 43.2 | 138.43% | 8.04% | | --- | --- | --- | --- | --- | | 京城机电股 ...